

NOVO NORDISK A S  
Form 6-K  
October 30, 2012

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

**October 30, 2012**

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_



## Company Announcement

30 October 2012

## Novo Nordisk A/S – Share repurchase programme

On 9 August 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk has repurchased B shares for an amount of DKK 2.0 billion in the period from 9 August 2012 to 29 October 2012. The programme is now concluded.

Since the announcement as of 22 October 2012, the following transactions have been made under the programme:

|  | <b>Number of shares</b> | <b>Average purchase price</b> | <b>Transaction value, DKK</b> |
|--|-------------------------|-------------------------------|-------------------------------|
| <b>Accumulated, last announcement</b>  | <b>1,904,048</b>        |                               | <b>1,767,040,823</b>          |
| 22 October 2012                        | 40,794                  | 969.88                        | 39,565,236                    |
| 23 October 2012                        | 40,211                  | 967.96                        | 38,922,788                    |
| 24 October 2012                        | 40,375                  | 965.65                        | 38,988,284                    |
| 25 October 2012                        | 39,546                  | 967.91                        | 38,277,119                    |
| 26 October 2012                        | 39,518                  | 934.06                        | 36,912,349                    |
| 29 October 2012                        | 43,210                  | 932.50                        | 40,293,334                    |
| <b>Accumulated under the programme</b> | <b>2,147,702</b>        |                               | <b>1,999,999,933</b>          |

With the transactions stated above, Novo Nordisk owns a total of 17,189,296 treasury shares, corresponding to 3.1% of the share capital. The total amount of shares in the company is 560,000,000 including treasury shares.

Company Announcement No 69 / 2012

Page 1 of 2

|                         |               |               |                 |          |
|-------------------------|---------------|---------------|-----------------|----------|
| <b>Novo Nordisk A/S</b> | Novo Allé     | Telephone:    | Internet:       | CVR no:  |
| Investor Relations      | 2880 Bagsværd | +45 4444 8888 | novonordisk.com | 24256790 |
|                         | Denmark       | Telefax:      |                 |          |
|                         |               | +45 4444 6626 |                 |          |

---

Novo Nordisk expects to repurchase B shares worth DKK 12.0 billion during a 12 month period beginning 2 February 2012. As of 29 October 2012, Novo Nordisk has repurchased a total of 12,513,460 B shares equal to a transaction value of DKK 10,499,999,311.

*Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,300 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).*

Further information:

Media:

Anne Margrethe Hauge  
Tel: (+45) 4442 3450  
[amhg@novonordisk.com](mailto:amhg@novonordisk.com)

Investors:

Kasper Roseeuw Poulsen  
Tel: (+45) 4442 4303  
[krop@novonordisk.com](mailto:krop@novonordisk.com)

Frank Daniel Mersebach  
Tel: (+45) 4442 0604  
[fdni@novonordisk.com](mailto:fdni@novonordisk.com)

Lars Borup Jacobsen  
Tel: (+45) 3075 3479  
[lbpj@novonordisk.com](mailto:lbpj@novonordisk.com)

*In North America:*

Ken Inchausti  
Tel: (+1) 609 514 8316  
[kiau@novonordisk.com](mailto:kiau@novonordisk.com)

Jannick Lindegaard  
Tel: (+1) 609 786 4575  
[jlis@novonordisk.com](mailto:jlis@novonordisk.com)

Investor Relations 2880 Bagsværd +45 4444 8888 novonordisk.com 24256790

Denmark

Telefax:

+45 4444 6626

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: October 30, 2012

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer

---



